News & Videos - EXACT SCIENCES CORP.

Exact Sciences Announces Preliminary Fourth Quarter 2023 Results PR Newswire MADISON, Wis., Jan. 7, 2024 Anticipates record fourth-quarter revenue, expects full-year 2024 revenue of $2.83 billion , submits next-generation Cologuard ® to FDA Announces Chief Financial Officer succession plan Highlighted announcements: Expects total fourth quarter revenue of $645.5 - $647.5 million , an increase of 17% compared to the fourth quarter of 2022, with Screening revenue of $486.0 - $487.0 million and...

Exact Sciences to participate in J.P. Morgan Healthcare Conference PR Newswire MADISON, Wis., Jan. 2, 2024 MADISON, Wis. , Jan. 2, 2024 /PRNewswire/ -- Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced that company management will participate in the following conference and invited investors to participate by webcast. J.P. Morgan Healthcare Conference, San Francisco Presentation followed by Q&A on Monday, January 8, 2024 at 2:15...

Exact Sciences Awards Grants to 23 Organizations Focused on Increasing Colorectal Cancer Screenings PR Newswire MADISON, Wis., Dec. 7, 2023 MADISON, Wis. , Dec. 7, 2023 /PRNewswire/ -- Exact Sciences, a leading provider of cancer screening and diagnostic tests, announced today that it awarded $1.3 million to 23 organizations through its Funding Opportunities for CRC Screening Uptake Strategies (FOCUS) Program. Grant recipients are committed to improving colorectal cancer (CRC) screening rates...

Exact Sciences Presents Multiple Studies at San Antonio Breast Cancer Symposium Supporting Optimization and Individualization of Therapy for Breast Cancer Patients PR Newswire MADISON, Wis., Nov. 30, 2023 Updated TAILORx follow-up data showing the integration of clinico-pathologic criteria and Recurrence Score ® results to refine distant recurrence risk estimates New concordance analysis supporting the generation of Oncotype DX ® results from core needle biopsy to personalize treatment...

Exact Sciences Files Patent Infringement Lawsuit Against Geneoscopy PR Newswire MADISON, Wis., Nov. 17, 2023 Company asserts that Geneoscopy infringed patented technology central to its Cologuard colorectal cancer screening test MADISON, Wis. , Nov. 17, 2023 /PRNewswire/ -- Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced that it has filed a lawsuit against Geneoscopy, Inc. in the United States District Court for the District of...

Exact Sciences Announces Third-Quarter 2023 Results PR Newswire MADISON, Wis., Nov. 1, 2023 Reports record revenue, delivers more than a million test results, raises full-year guidance Third -quarter 2023 highlights Total third quarter revenue of $628 million , an increase of 20%, or 23% on a core revenue basis Delivered more than 1 million test results, including a record for Cologuard® and Oncotype DX® tests Full-year 2023 revenue and adjusted EBITDA guidance midpoints raised by $28 million...

Exact Sciences to participate in November investor conferences PR Newswire MADISON, Wis., Nov. 1, 2023 MADISON, Wis. , Nov. 1, 2023 /PRNewswire/ -- Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced that company management will participate in the following conferences and invited investors to participate by webcast. Stifel Healthcare Conference, New York Fireside chat on Tuesday, November 14, 2023 at 10:20 a.m. ET Jefferies London...

Next-Generation Cologuard® Test Demonstrates High Sensitivity and Specificity in Pivotal BLUE-C Study, Significantly Outperforming Fecal Immunochemical Testing (FIT) for Cancer and Precancer Detection PR Newswire MADISON, Wis., Oct. 22, 2023 American College of Gastroenterology (ACG) gives BLUE-C study late breaker status at 2023 annual meeting with presentation of the only head-to-head study results versus FIT at ACG High specificity for next-generation Cologuard test expected to minimize...

Exact Sciences Advances Early Cancer Detection and Precision Oncology Programs with Data Presentations at ESMO 2023 Annual Congress PR Newswire MADISON, Wis., Oct. 20, 2023 MADISON, Wis. , Oct. 20, 2023 /PRNewswire/ -- Exact Sciences Corp. (NASDAQ: EXAS), a leading provider of cancer screening and diagnostic tests, today announced it will present new data supporting the company's research in early cancer detection, genomic testing, and treatment guidance at the 2023 European Society for Medical...

Exact Sciences schedules third quarter 2023 earnings call PR Newswire MADISON, Wis., Oct. 9, 2023 MADISON, Wis. , Oct. 9, 2023 /PRNewswire/ -- Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced that the company plans to release its third quarter 2023 financial results after the close of the U.S. financial markets on November 1, 2023 . Following the release, company management will host a webcast and conference call at 5 p.m. ET to...

Exact Sciences to Present Late-Breaking Data from Pivotal BLUE-C Study on Next-Generation Cologuard at ACG 2023 PR Newswire MADISON, Wis., Oct. 9, 2023 MADISON, Wis. , Oct. 9, 2023 /PRNewswire/ -- Exact Sciences Corp. (NASDAQ: EXAS), a leading provider of cancer screening and diagnostic tests, today announced the company will present late-breaking data on next-generation Cologuard ® from the BLUE-C pivotal trial during the American College of Gastroenterology (ACG) Annual Meeting, taking place...

Exact Sciences to participate in September investor conference PR Newswire MADISON, Wis., Sept. 1, 2023 MADISON, Wis. , Sept. 1, 2023 /PRNewswire/ -- Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced that company management will participate in the following conference and invited investors to participate by webcast. Baird Global Healthcare Conference, New York Fireside chat on Tuesday, September 12, 2023 at 10:50 a.m. ET The webcast...

Exact Sciences Lab and OncoExTra Test Selected by National Cancer Institute for ComboMATCH Clinical Trials PR Newswire MADISON, Wis., Aug. 30, 2023 ComboMATCH trials will use Exact Sciences' new OncoExTra ™ therapy selection test to analyze tumor samples for participants in this large precision medicine initiative Participation in trials reinforces company's commitment to enable delivery of personalized cancer care MADISON, Wis. , Aug. 30, 2023 /PRNewswire/ -- Exact Sciences Corp. (NASDAQ:...

Not a Wall, But an Obstacle Course: New Findings Reveal Why 45-Year-Olds Are Avoiding Colorectal Cancer Screenings PR Newswire MADISON, Wis., Aug. 21, 2023 First-of-its-kind research from the "I Am 45" poll explores why 45-year-olds are not getting screened for deadly colorectal cancer despite national screening guidelines 1,2 From lack of time to lack of health insurance, low awareness and fears of learning bad news: barriers are as unique and varied as the regions and demographics of the U.S....

Exact Sciences Announces Second-Quarter 2023 Results PR Newswire MADISON, Wis., Aug. 1, 2023 Reports record results, generates positive free cash flow, raises full-year guidance Second -quarter 2023 highlights Total second quarter revenue of $622 million , an increase of 19%, and $617 million of core revenue, an increase of 24% Cash provided by operating activities was $100 million and free cash flow was $66 million Full-year 2023 revenue and adjusted EBITDA guidance raised by $54 million and...

Exact Sciences schedules second quarter 2023 earnings call PR Newswire MADISON, Wis., July 10, 2023 MADISON, Wis. , July 10, 2023 /PRNewswire/ -- Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced that the company plans to release its second quarter 2023 financial results after the close of the U.S. financial markets on August 1, 2023 . Following the release, company management will host a webcast and conference call at 5 p.m. ET to...

Exact Sciences Advances Innovative Cancer Technologies and Approaches Through Visionary Collaborations PR Newswire MADISON, Wis., June 21, 2023 Agreements with Broad Institute of MIT and Harvard provide exclusive license to next-generation technology for ultra-sensitive detection of molecular residual disease and ongoing research Collaboration with Baylor Scott & White creates real-world experience and evidence supporting Exact Sciences' multi-cancer early detection approach MADISON, Wis. , June...

Next-generation Cologuard Test Demonstrates 94 Percent Sensitivity for Colorectal Cancer at 91 Percent Specificity, Raising the Bar in Non-invasive Screening PR Newswire MADISON, Wis., June 20, 2023 BLUE-C study met all endpoints, showing improved cancer sensitivity, specificity, and precancer sensitivity 20,000-participant study reflects racial and ethnic diversity of the U.S. Company plans to complete FDA submission for next-generation Cologuard by end of 2023 MADISON, Wis. , June 20, 2023...

EXACT SCIENCES EARNS 2023 GREAT PLACE TO WORK® CERTIFICATION™ PR Newswire MADISON, Wis., June 1, 2023 Award marks fifth consecutive year company has received prestigious distinction MADISON, Wis. , June 1, 2023 /PRNewswire/ -- Exact Sciences Corp. (NASDAQ: EXAS), a leading provider of cancer screening and diagnostic tests, announced today that the company has been certified as a 2023 Great Place To Work ® for the fifth consecutive year. The certification is based on the results of a...

Exact Sciences to participate in June investor conferences PR Newswire MADISON, Wis., June 1, 2023 MADISON, Wis. , June 1, 2023 /PRNewswire/ -- Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced that company management will participate in the following conferences and invited investors to participate by webcast. Jefferies Healthcare Conference, New York Fireside chat on Wednesday, June 7, 2023 at 2:00 p.m. ET William Blair 43 rd...